Multibagger PB Fintech gains 136% YTD: Can you still buy it?

The stock of fintech major PB Fintech are in focus in Friday's trade (November 29) after brokerages have reierated their previous calls on the counter. Bernstein has continued with its earlier 'outperform' call on the stock with the target of Rs 1,720.

This is a potential decline of 9 per cent from the previous close.

Likewise, another global brokerage BofA has continued with its neutral rating and a target has been decided at Rs 1,850- implying downside of 2 per cent.

The decline in the stock price is antiicipated even as BofA believes core momentum remains strong. Also, the brokerage iterated that downside risks for PB Health remains low and offers upside optionality.

Also, the brokerage underscored that the focus of PB's health-care foray is to solve claims & improve insurance penetration.  Furthermore, the global brokerage added on the back of limited investment of less than $100 million from PB Fintech, it expects worse-case impact may be much lower.

Think PB Health offers an upside optionality from 3-4 years perspective, it added.

PB Fintech Q2 results

Net profit of the company was reported at Rs 50.67 crore in the quarter ended September 2024 as against net loss of Rs 20.24 crore during the previous quarter ended September 2023.

Sales also grew 43.81 per cent to Rs 1167.23 crore in the quarter ended September 2024 as against Rs 811.63 crore during the previous quarter ended September 2023.